| 1 |
32527038 | Adverse Drug Reactions in the Emergency Department: Is There a Role for Pharmacogenomic Profiles at Risk?-Results from the ADRED Study. | 2020 Jun 9 |
2 |
| 2 |
32047440 | Phenprocoumon Dose Requirements, Dose Stability and Time in Therapeutic Range in Elderly Patients With CYP2C9 and VKORC1 Polymorphisms. | 2019 |
2 |
| 3 |
24224579 | A new algorithm for weekly phenprocoumon dose variation in a southern Brazilian population: role for CYP2C9, CYP3A4/5 and VKORC1 genes polymorphisms. | 2014 Apr |
1 |
| 4 |
23519598 | Quantifying the effect of covariates on concentrations and effects of steady-state phenprocoumon using a population pharmacokinetic/pharmacodynamic model. | 2013 May |
1 |
| 5 |
22409277 | An evaluation of gene-gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. | 2012 May |
2 |
| 6 |
21063236 | Dependency of phenprocoumon dosage on polymorphisms in the VKORC1, CYP2C9, and CYP4F2 genes. | 2011 Jan |
1 |
| 7 |
21636598 | Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. | 2011 Aug |
3 |
| 8 |
20020283 | Genetic determinants of acenocoumarol and phenprocoumon maintenance dose requirements. | 2010 Mar |
1 |
| 9 |
18629445 | Dependency of phenprocoumon dosage on polymorphisms in the VKORC1 and CYP2C9 genes. | 2009 Aug |
1 |
| 10 |
17955831 | [Oral anticoagulation and pharmacogenetics: importance in the clinical setting]. | 2007 Sep 12 |
2 |
| 11 |
16580879 | Left ventricular non-compaction associated with a genetic variant of the CYP2C9 gene. | 2006 Aug |
1 |
| 12 |
16372822 | Comparative pharmacokinetics of vitamin K antagonists: warfarin, phenprocoumon and acenocoumarol. | 2005 |
1 |
| 13 |
15128047 | Effects of CYP2C9 polymorphisms on the pharmacokinetics of R- and S-phenprocoumon in healthy volunteers. | 2004 Jan |
2 |
| 14 |
15128048 | The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. | 2004 Jan |
1 |
| 15 |
15213846 | The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. | 2004 Jul |
3 |
| 16 |
15536456 | Effects of cytochrome P450 2C9 polymorphisms on phenprocoumon anticoagulation status. | 2004 Nov |
2 |
| 17 |
15742978 | Genetic polymorphisms of cytochrome P450 2C9 causing reduced phenprocoumon (S)-7-hydroxylation in vitro and in vivo. | 2004 Sep |
1 |
| 18 |
12724615 | Pharmacogenetics of oral anticoagulants. | 2003 May |
1 |
| 19 |
12728288 | Determination of bleeding risk using genetic markers in patients taking phenprocoumon. | 2003 Jul |
1 |
| 20 |
10640513 | Prediction of pharmacokinetic drug/drug interactions from In vitro data: interactions of the nonsteroidal anti-inflammatory drug lornoxicam with oral anticoagulants. | 2000 Feb |
1 |
| 21 |
10562412 | Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. | 1999 Dec 1 |
2 |